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Association of Serum Uric Acid With Level of Blood 
Pressure in Type 2 Diabetic Patients
Mahmoud Rafieian-Kopaei,1 Saeed Behradmanesh,2  
Soleiman Kheiri,2 Hamid Nasri3 
This study was conducted to investigate the association between 
serum uric acid level and blood pressure in type 2 diabetes mellitus. 
Sixty patients with type 2 diabetes mellitus were enrolled to the 
study. None of the patients had a history of gout, were treated 
with allopurinol, or were treated with antihypertensive drugs 
previously. The mean duration of DM was 9.2 ± 4.9 years. The mean 
serum creatinine level was 0.98 ± 0.22 mg/dL, and the mean serum 
UA level was 4.4 ± 1.2 mg/dL. The mean protein level in 24-hour 
urine sample was 388 ± 22 mg/d. The mean systolic and diastolic 
blood pressure values were 133.0 ± 13.0 mm Hg and 84.0 ± 7.4 mm 
Hg, respectively. There was no significant difference in levels of 
serum uric acid, hemoglobin A1c, serum creatinine, proteinuria, or 
systolic and diastolic pressure between the men and the women. 
A significant positive correlation was seen between serum UA and 
systolic (r = 0.312, P = .02) and diastolic blood pressure (r = 0.297, 
P = .03). Results of this study suggest that serum uric acid had a 
strong association with levels of systolic and diastolic blood pressure 
in type 2 diabetic patients. More attention to the serum uric acid 
level and treatment of hyperuricemia could halt the progress of 
diabetic nephropathy.
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Uric acid (UA), as the final oxidation product 
of purine catabolism, has been associated with 
various clinical conditions such as diabetes mellitus 
(DM) and atherosclerotic disease.1 Recent studies 
suggest that UA is a relevant and independent 
risk factor for kidney disease, particularly in 
patients with hypertension.1-3 It was shown that 
hyperuricemia, induced by a uricase inhibitor, 
triggered hypertension and impaired nitric oxide 
generation in the macula densa, while both 
hypertension and renal injury are reduced by 
inducing nitric oxide.4-6 The mechanism by which 
uric acid may cause organ damage is not fully 
understood; however, there is increasing evidence 
that endothelial dysfunction is a mechanism 
whereby this substance may affect kidney function 
and structure.7-9 The aim of this observational study 
was to determine whether baseline serum uric acid 
levels are associated with blood pressure in type 
2 DM with preserved kidney function at baseline 
and without a previous history of cardiovascular 
disease or gout.
A cross-sectional study was carried out on 60 
patients with type 2 DM. None of the patients 
had a history of gout and none was treated 
with allopurinol or antihypertensive drugs. 
Anthropometric measurements were collected, 
including height, body weight, and body mass 
index. Resting systolic blood pressures and the 
5th phase diastolic blood pressures were measured 
three times, while the participants were seated, and 
the 2nd and 3rd measurements were averaged.10,11 
Uric Acid and Blood Pressure in Diabetics—Rafieian-Kopaei et al
153Iranian Journal of Kidney Diseases | Volume 8 | Number 2 | March 2014
Hypertension was defined as a blood pressure of 
140/90 mmHg or higher or currently receiving 
antihypertensive treatment.10,11 Venous blood 
samples were obtained in the fasting state for 
determination of serum levels of creatinine, uric 
acid, and hemoglobin A1c (reference range, 4% to 
6%). In addition, 24-hour urine protein excretion 
was measured.
Results were expressed as mean ± standard 
deviation and comparisons were considered 
significant when two-sided P value was less than 
.05. The independent-samples t test was used for 
comparison of variables between men and women. 
The Spearman rho coefficient correlation was used 
for evaluating correlations among variables. For 
association of serum uric acid with levels of blood 
pressure, the partial correlation test was used with 
adjustment for age, duration of DM, and serum 
creatinine level.
Of the 60 participants, 56.7% were women. 
The mean of age was 57.0 ± 8.3 years. The mean 
duration of DM was 9.2 ± 4.9 years. The mean 
serum creatinine level was 0.98 ± 0.22 mg/dL, and 
the mean serum UA level was 4.4 ± 1.2 mg/dL. 
The mean protein level in 24-hour urine sample 
was 388 ± 22 mg/d (median, 303.5 mg/d). The 
mean systolic and diastolic blood pressure values 
were 133.0 ± 13.0 mm Hg and 84.0 ± 7.4 mm Hg, 
respectively. In this study, there was no significant 
difference in serum UA, HbA1c, or serum creatinine 
between the men and the women. Similarly, there 
was no significant difference in proteinuria and 
levels of systolic or diastolic pressure between the 
two groups. A significant positive correlation was 
seen between serum UA and systolic (r = 0.312, 
P = .02) and diastolic blood pressure (r = 0.297, 
P = .03).
In the present study, we found a significant 
positive correlation of serum UA with systolic and 
diastolic blood pressure. No significant difference 
was found in serum uric acid, HbA1c, or creatinine, 
between the men and women. Similarly, no 
significant difference was observed in proteinuria 
and levels of systolic or diastolic pressure between 
the men and the women. Increasing evidence 
supports a causal role for UA in hypertension 
and associated target organ damage in humans, 
especially in women.1,4,7,12,13 Recent studies have 
shown that experimental hyperuricemia in rats 
induce hypertension.1,4,7,12,13 The mechanism 
by which urate causes a deleterious effect may 
be related to oxidative stress and diminished 
production of nitric oxide and renal arteriolar 
damage due to proliferation of vascular smooth 
muscle cells.4,7,11-17
To find the association of serum UA and 
endothelial function, Zoccali and coworkers 
conducted a study on untreated hypertensive 
patients. They found that serum UA was inversely 
correlated with flow-mediated vasodilatation.18 
Diabetic nephropathy is now the major cause of end-
stage renal disease.6,17- 20 Various epidemiological 
studies have also demonstrated that serum UA is 
associated with diabetic nephropathy, suggesting 
a potential role for uric acid in the disease 
pathogenesis.1,4,7 Given these facts, we also could 
show that UA played a pathological role in the 
development of hypertension and in type 2 diabetic 
patients. Hypertension per se is an aggravating 
factor of diabetic nephropathy; thus, more attention 
to serum UA level and appropriate treatment of 
hyperuricemia could attenuate progression of 
diabetic nephropathy.
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